NCT06230224: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 2 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06230224 |
|---|---|
| Title | A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 15, 2024 |
| Completion date | May 14, 2027 |
| Required reporting date | May 13, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |